http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020170033-A8

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e02cbcee5fd69af5dec3b32e563b558
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-327
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2020-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9fc208ecfe5ef52db5aa7061d62d2b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ab0836cd5126d989b6b5610d93d63bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_700555544b8572ca783d0f461becf26d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33fb2c08e9fefaa50e0c8630496d3fdc
publicationDate 2022-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2020170033-A8
titleOfInvention Method for treatment of moderate to severe erythema symptoms in rosacea patients
abstract A regimen for the therapeutic treatment of moderate to severe erythema symptoms in rosacea patients, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 12 weeks, to achieve a percentage decrease of about 60% in a population exhibiting moderate to severe erythema symptoms when measured at about 12 weeks after initial treatment of the population with the pharmaceutical composition.
priorityDate 2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7187
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555171
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393257

Total number of triples: 28.